Related Experiment Video
Updated: Jul 6, 2026
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Lanreotide Autogel for persistent diabetic macular edema
Maria C Hernaez-Ortega1, Enrique Soto-Pedre, José A Piniés
1European Innovative Biomedicine Institute (EIBI), Cantabria, Spain. concha.hernaez@eibi.es
Diabetes Research and Clinical Practice
|March 28, 2008
Summary
Monthly injections of lanreotide Autogel effectively treated persistent cystoid macular edema in patients with poorly controlled diabetes. This prolonged formulation offers a new treatment option for refractory diabetic macular edema.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diffuse diabetic macular edema (DDME) often proves resistant to standard therapies.
- Poorly controlled diabetes mellitus is a leading cause of vision loss due to complications like DDME.
Observation:
- Persistent cystoid macular edema (CME) in patients with uncontrolled diabetes was investigated.
- Conventional treatments for DDME showed limited efficacy in the studied patient cohort.
Findings:
- A new prolonged-release formulation of lanreotide, administered via monthly subcutaneous injections, demonstrated significant effectiveness.
- Lanreotide Autogel provided a viable therapeutic alternative for patients with refractory DDME and persistent CME.
Implications:
- Monthly lanreotide Autogel injections represent a promising new treatment strategy for refractory diabetic macular edema.
- This formulation may improve visual outcomes and quality of life for patients with challenging diabetic eye disease.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...